Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Insulin Resistance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Alpelisib Pilot & Feasibility Study

NCT05733455 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT05733455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05733455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Insulin Resistance in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Alpelisib Pilot & Feasibility Study
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Completed
Start date
May 9, 2023
Completion date
December 1, 2023
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, hyperinsulinemia, insulin resistance